SEARCH

SEARCH BY CITATION

References

  • 1
    Abell TL, Bernstein VK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006; 18: 26383.
  • 2
    Schmid R, Schusdziarra V, Allescher HD, Bofilias I, Buttermann G, Classen M. Effect of motilin on gastric emptying in patients with diabetic gastroparesis. Diabetes Care 1991; 14: 658.
  • 3
    Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 1989; 257: G4704.
  • 4
    Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322: 102831.
  • 5
    Annese V, Lombardi G, Frusciante V, Germani U, Andriulli A, Bassotti G. Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997; 11: 599603.
  • 6
    Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 108996.
  • 7
    Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001; 49: 395401.
  • 8
    Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 165361.
  • 9
    Tack J, Peeters T. What comes after macrolides and other motilin stimulants? Gut 2001; 49: 3178.
  • 10
    Peeters TL. GM-611 (Chugai Pharmaceutical). Curr Opin Investig Drugs 2001; 2: 5557.
  • 11
    Clark MJ, Wright T, Bertrand PP, et al. Erythromycin derivatives ABT 229 and GM 611 act on motilin receptors in the rabbit duodenum. Clin Exp Pharmacol Physiol 1999; 26: 2425.
  • 12
    Delgado-Aros S, Locke GR, 3rd, Camilleri M, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004; 99: 18016.
    Direct Link:
  • 13
    Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002; 97: 60411.
    Direct Link:
  • 14
    Drossman DA, Corrazziari E, Delvaux M, et al. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates, 2006.
  • 15
    Drossman DA, Corrazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II: The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. McLean, VA: Degnon Associates, 2000.
  • 16
    Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 155379.
  • 17
    De Block CE, De Leeuw IH, Pelckmans PA, Callens D, Maday E, Van Gaal LF. Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. Diabetes Care 2002; 25: 9127.
  • 18
    Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005; 17: 32531.
  • 19
    Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol 2003; 98: 26471.
    Direct Link: